Mutz will play a key role in the St. Jude Strategic Plan and future hospital expansion.
Quality improvement effort shows the way to enhance vaccination among health care providers and protect patients.
St. Jude researchers pinpoint the cell type that turns malignant in rhabdomyosarcoma, which could open the path for better treatments.
Read about the TP53 gene variations that leave young people more likely to develop acute lymphoblastic leukemia and to die as a result.
The scientists showed that certain memory T cells develop from T cells originally made by the body for another role.
Early results suggest gene therapy is well tolerated and effective for babies with X-linked severe combined immunodeficiency disorder, or "bubble boy" disease.
A drug widely used against malaria sensitizes the high-risk leukemia BCR-ABL positive ALL to a precision medicine and may enhance treatment.
St. Jude scientists, clinicians and leadership highlighted at the annual American Society of Hematology in Atlanta. Read the latest.
Researchers have discovered how a linkage between two proteins in AML enables cancer cells to resist chemotherapy- disrupting the linkage could become a treatment pathway.
Higher doses of hydroxyurea in children with sickle cell disease boosts their fetal hemoglobin levels and significantly reduces hospitalizations.
Explore more research news
More Research News
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Courageous patients. Resolute doctors. Caring staff. Inventive scientists. Their voices come alive in Promise magazine.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.